 |
|
Targeted therapy shows significant benefits over standard treatment for advanced kidney cancer
June 05, 2006ATLANTA— According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.
"This drug has shown more activity as a single agent against advanced kidney cancer than any other drug I've studied in the past 15 years," said the study's lead author Robert J. Motzer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). "I continue to be encouraged by its effectiveness in treating patients with this aggressive disease," said Dr. Motzer, who is a leader in the treatment of kidney cancer and conducted the earliest clinical trials on sunitinib (initially referred to as SU11248).
Interferon-alpha (IFN-Ü) is one of the standard treatments for advanced kidney cancer, however only about 15 percent of patients respond to this immunotherapy. Sunitinib targets receptors on kidney cancer cells that may play a role in tumor growth and the development of blood vessels that feed a tumor. Previous clinical trials, also led by Dr. Motzer, showed that sunitinib caused some renal cell cancers to shrink, but this study is the first to demonstrate its effectiveness as a first-line therapy compared with standard cytokine therapy with IFN-Ü.
The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-Ü. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN-Ü as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-Ü. This outcome was statistically significant and met the primary question asked by investigators in the trial. In addition, 31 percent of the patients in the sunitinib arm of the study experienced substantial tumor shrinkage compared with 6 percent of the patients receiving the standard treatment.
"This drug offers new hope for the initial treatment of patients battling metastatic kidney cancer, which is otherwise resistant to chemotherapy," said Dr. Motzer.
Memorial Sloan-Kettering Cancer Center
The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-Ü. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN-Ü as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-Ü. This outcome was statistically significant and met the primary question asked by investigators in the trial. In addition, 31 percent of the patients in the sunitinib arm of the study experienced substantial tumor shrinkage compared with 6 percent of the patients receiving the standard treatment.
"This drug offers new hope for the initial treatment of patients battling metastatic kidney cancer, which is otherwise resistant to chemotherapy," said Dr. Motzer.
Memorial Sloan-Kettering Cancer Center
Kidney Cancer Current Events and Kidney Cancer News RSSNew data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
Stem cell protein offers a new cancer target
A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.
2-drug combination appears safe and active in metastatic kidney cancer
Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial.
Finding Will Improve Accuracy of Cancer Diagnosis
Van Andel Research Institute (VARI) investigators working in collaboration with Cleveland Clinic researchers have determined that two types of kidney tumors previously thought to be different diseases are actually variations of the same disease.
Does a person's insurance coverage affect their access to quality cancer care?
Does a person's insurance coverage affect their access to quality cancer care? According to researchers at Fox Chase Cancer Center, insurance coverage may not only affect a patient's access to health care, but also the quality of care they receive.
Robotic assisted kidney cancer surgery proves to be beneficial to patients
Fox Chase Cancer Center researchers find that outcomes of robotic assisted kidney cancer surgery, when performed by experienced surgeons at high volume centers, prove more beneficial to patients when compared to open surgery.
Getting down to cancer basics
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers.
Castrate resistant prostate cancer: New therapeutic approaches
Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.
Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
Freezing kidney tumors-using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery-should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller. And, this treatment-interventional cryoablation-is a viable option for people with larger tumors, according to two studies presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting.
Roadkill study could speed detection of kidney cancer
Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer.
More Kidney Cancer Current Events and Kidney Cancer News Articles
 |
100 Questions & Answers About Kidney Cancer (100 Questions & Answers about) by Steven C. Campbell (Author) There are 37,000 cases of kidney (renal cell) cancer in the US and 13,000 related deaths annually. 100 Questions and Answers About Kidney Cancer explains all aspects of the disease resulting in full awareness of what to expect when battling kidney cancer. |
 |
Kidney Cancer: A New Approach (Home Use) Most people have two functional kidneys which help regulate electrolytes such as sodium, potassium, calcium, and magnesium. Kidney tumors may change these important functions and can lead to a diagnosis of kidney cancer. On this program we spend time with courageous patients who are coping with their kidney cancer by seeking a new approach. Kidney Cancer is part of the award winning public television series Healthy Body, Healthy Mind. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Johns Hopkins Patients' Guide to Kidney Cancer (John Hopkins Medicine) by Michael A. Carducci (Author), Janet R. Walczak (Author) The Johns Hopkins Patients Guide to Kidney Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining kidney cancer treatments from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and provides valuable tools to help you to put together your plan of care. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. |
 |
Standard Process Renafood 90 Tablets by Standard Process |
 |
Kidney Cancer: The Silent Destroyer Directed By: (c) Information Television Network |
 |
Kidney Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Kidney Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Kidney Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Kidney Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Beating Kidney Cancer Together Sweatshirt XXX-Large White by Shop Zeus |
 |
Cure Kidney Cancer Keychain by Design a Product LLC Text on keychain: Cure Kidney Cancer * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
 |
Faster Than Glucosamine Joint Health Supplement - 90 Ct Softgels, 4.5-Ounce Boxes by FASTER THAN GLUCOSAMINE "Clinical research indicates that Faster Than Glucosamine! or FTG capsules, may be the world’s most effective natural anti-inflammatory supplement. Faster Than Glucosamine! is NOT glucosamine which is a shellfish extract. Rather, FTG is formulated with an extract from beef. Many people have heard how omega3 and fish oils are healthy due to their anti-inflammatory properties and for this reason we are often told to eat more fish and less beef. However not all beef causes inflammation. Nature has provided very potent anti-inflammatory oils within beef, which are then used to make FTG. IMPROVEMENT IN JUST 2 WEEKS: At the 2007 Scripps Integrated Medical Conference in California, this beef extract was awarded the best paper out of the 90 papers presented due to the outstanding results... |
 |
DANGER CADMIUM CANCER HAZARD CAN CAUSE LUNG AND KIDNEY DISEASE AUTHORIZED PERSON by Accuform Signs ADHESIVE VINYL (VS) Stick with Adhesive Vinyl for light-duty applications. The ideal choice for a variety of indoor, and sheltered outdoor, marking needs. Easily mounts to all curved areas such as pipes, poles and secondary containers.Material Features: 4-mil thick surface printed matte surface. Permanent acrylic adhesive. Moisture-resistant. Service temperature range: -20°F to 140°F. Durability: 2 years outdoors. Square corners and scored backing for quick peel-off and application. |
| © 2009 BrightSurf.com |